ABBOTT REPORTS POSITIVE DATA FOR HUMIRA IN ANKYLOSING SPONDYLITIS

Abbott has revealed positive new results of two analyses from a Phase III study of Humira in ankylosing spondylitis (AS), an inflammatory disease of the spine and spinal joints.

The first analysis demonstrated the ability of Humira to maintain the reduction of signs and symptoms in AS patients at 12 weeks through 52 weeks of treatment.

A second analysis demonstrated that Humira rapidly and significantly reduced pain and fatigue in patients with AS as early as two weeks compared with placebo and that the improvement was maintained for at least 24 weeks.